Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer (Q36185608)

12 August 2017

1 reference

title

Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer (English)

1 reference

12 August 2017

Antonio Jimeno

1

1 reference

PubMed ID

16001950

12 August 2017

Michael Carducci

series ordinal

2

1 reference

12 August 2017

1 June 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

419-427

1 reference

12 August 2017

3

1 reference

Hormone refractory disease

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Clinical trial design for target-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

The endothelin system and its potential as a therapeutic target in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Endothelin receptors as novel targets in tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Growth regulatory properties of endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Role of endothelin in human hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

New therapeutics that antagonize endothelin: promises and frustrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Role of endothelin-1 in neovascularization of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Atrasentan: targeting the endothelin axis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.419

21 January 2018

Identifiers

DOI

10.1586/14737140.5.3.419

1 reference

12 August 2017

1 reference

PubMed ID

16001950